z-logo
open-access-imgOpen Access
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Author(s) -
Richard J. Fitzgerald,
Laura Dickinson,
Laura Else,
Tom Fletcher,
Colin Hale,
Alieu Amara,
Lauren Walker,
Sujan Dilly Penchala,
Rebecca Lyon,
Victoria Shaw,
William Greenhalf,
Katie Bullock,
Lara Lavelle-Langham,
Helen Reynolds,
Wendy Painter,
Wayne Holman,
Sean Ewings,
Gareth Griffiths,
Saye Khoo
Publication year - 2022
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciac199
Subject(s) - prodrug , saliva , pharmacokinetics , nucleoside , medicine , nucleoside analogue , clinical trial , transmission (telecommunications) , covid-19 , coronavirus , respiratory system , pharmacology , gastroenterology , virology , chemistry , biochemistry , disease , infectious disease (medical specialty) , electrical engineering , engineering
ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at sites of SARS-CoV-2 transmission in twelve patients enrolled in AGILE CST-2 (NCT04746183). Saliva, nasal and tear concentrations were 3, 21 and 22% that of plasma. Saliva and nasal NHC concentrations were significantly correlated with plasma (p<0.0001).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom